FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Novamine Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Administration of amino acids solutions at excessive rates or to patients with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Conservative doses of amino acids should be given to these patients, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid administration should be discontinued and the patient’s clinical status re-evaluated.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.
Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Novamine® 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when:
— Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy;
— Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks;
— Tube feeding methods alone cannot provide adequate nutrition.
History
There is currently no drug history available for this drug.
Other Information
Novamine® 15% Amino Acids Injection in a Pharmacy Bulk Package is a sterile, clear, nonpyrogenic solution of essential and nonessential amino acids for intravenous infusion in parenteral nutrition following appropriate dilution.
Novamine® 15% in a Pharmacy Bulk Package is not for direct infusion. It is a sterile dosage from which contains several single doses for use in a pharmacy admixture program in the preparation of intravenous parenteral fluids.
Each 100 mL contains:
Essential Amino Acids |
||
Lysine (from Lysine Acetate, USP)……………………………………................1.18 |
g |
|
Leucine, USP……………………………………………………………..............1.04 |
g |
|
Phenylalanine, USP……………………………………........................................1.04 |
g |
|
Valine, USP……………………………………………………………..................960 |
mg |
|
Isoleucine, USP………………………………………............................................749 |
mg |
|
Methionine, USP………………………………………..........................................749 |
mg |
|
Threonine, USP………………………………………............................................749 |
mg |
|
Tryptophan, USP………………………………………..........................................250 |
mg |
|
Nonessential Amino Acids |
||
Alanine, USP…………………………………………..........................................2.17 |
g |
|
Arginine, USP………………………………………….........................................1.47 |
g |
|
Glycine, USP…………………………………………..........................................1.04 |
g |
|
Histidine, USP………………………………………….........................................894 |
mg |
|
Proline, USP…………………………………………………………….................894 |
mg |
|
Glutamic Acid…………………………………………..........................................749 |
mg |
|
Serine, USP……………………………………………..........................................592 |
mg |
|
Aspartic Acid, USP……………………………………..........................................434 |
mg |
|
Tyrosine, USP…………………………………………............................................39 |
mg |
|
Sodium Metabisulfite, NF added……………………………………………...............30 |
mg |
|
Water for Injection, USP……………………………………………………................... |
qs |
|
Essential Amino Acids……………………………………………………….............6.7 |
g |
|
Nonessential Amino Acids………………………………………………….................8.3 |
g |
|
Total Amino Acids…………………………………………………………...............15.0 |
g |
|
Total Nitrogen………………………………………………………………..............2.37 |
g |
|
Acetate*…………………………………………………….........................................151 |
mEq/L |
|
Osmolarity (calculated)…………………………………….......................................1388 |
mOsmol/L |
|
pH……………………………………………………………………………....................5.6(5.2-6.0) |
||
*Acetate from Lysine Acetate, USP and acetic acid used for pH adjustment. |
The formulas for the individual amino acids are as follows:
Sources
Novamine Manufacturers
-
Hospira, Inc.
Novamine | Hospira, Inc.
The appropriate daily dose of amino acids to be used with dextrose or with dextrose and intravenous fat emulsion will depend upon the metabolic status and clinical response of the patient as therapy proceeds. Doses which achieve nitrogen equilibrium or positive balance are the most desirable. The dosage on the first day should be approximately half the anticipated optimal dosage and should be increased gradually to minimize glycosuria; similarly, withdrawal should be accomplished gradually to avoid rebound hypoglycemia.
Fat emulsion coadministration should be considered when prolonged (more than 5 days) parenteral nutrition is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat free TPN.
The amount administered is dosed on the basis of amino acids/kg of body weight/day. In general, two to three g/kg of body weight for neonates and infants with adequate calories are sufficient to satisfy protein needs and promote positive nitrogen balance. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE
Novamine® 15% in a Pharmacy Bulk Package is not intended for direct infusion. The container closure may be penetrated only once using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Once the closure is penetrated, the contents should be dispensed as soon as possible; the transfer of contents must be completed within 4 hours of closure entry. The bottle may be stored at room temperature (25°C) after the closure has been entered. Date and time of container entry should be noted in the area designated on the container label.
When using Novamine® 15% in patients with a need for fluid volume restriction, it can be diluted as follows:
Volume
Amount
Final Concentration
Novamine® 15%
500 mL
75 g
7.5%
Dextrose 70%
250 mL
175 g
17.5%
Intralipid® 20%
250 mL
50 g
5.0%
This will provide 1395 kilocalories (kcal) per 1000 mL of admixture with a ratio of 118 non-protein calories per gram of nitrogen and an osmolarity of 1561 mOsmol/L.
In patients where the need for fluid restriction is not so marked, either of the following regimens may be used dependent upon the energy needs of the patient.
Volume
Amount
Final Concentration
Novamine® 15%
500 mL
75 g
3.75%
Dextrose 50%
1000 mL
500 g
25%
Intralipid® 20%
500 mL
100 g
5%
This will provide 1500 kcal per 1000 mL of admixture with a ratio of 228 non-protein calories per gram of nitrogen and an osmolarity of 1633 mOsmol/L.
Volume
Amount
Final Concentration
Novamine® 15%
500 mL
75 g
3.75%
Dextrose 30%
1000 mL
300 g
15%
Intralipid® 10%
500 mL
50 g
2.5%
This will provide 935 kcal per 1000 mL of admixture with a ratio of 158 non-protein calories per gram of nitrogen and an osmolarity of 1128.5 mOsmol/L.
A. Total Parenteral Nutrition (Central Infusion)
In unstressed adult patients with no unusual nitrogen losses, a minimum dosage of 0.1 gram nitrogen (4.2 mL of Novamine® 15%) plus 4.4 grams (15 calories) of dextrose per kilogram of body weight per day are required to achieve nitrogen balance and weight stability. Intravenous fat emulsion may be used as a partial substitute for dextrose. This regimen provides a ratio of 150 non-protein calories per gram of nitrogen.
For patients stressed by surgery, trauma or sepsis, and those with unusual nitrogen losses, the dosage required for maintenance may be as high as 0.3 to 0.4 grams of nitrogen (13 to 17 mL Novamine® 15%) per kilogram of body weight per day, with proportionate increases in non-protein calories. Periodic assessment of nitrogen balance of the individual patient is the best indicator of proper dosage. Volume overload and glycosuria may be encountered at high dosage, and nitrogen balance may not be achieved in extremely hypermetabolic patients under these constraints. Concomitant insulin administration may be required to minimize glycosuria. Daily laboratory monitoring is essential.
Use of an infusion pump is advisable to maintain a steady infusion rate during central venous infusion.
B. Peripheral Nutrition
In patients for whom central venous catheterization is not advisable, protein catabolism can be reduced by peripheral use of diluted Novamine® 15% plus non-protein calorie sources. Dilution of 250 mL Novamine® 15% in 750 mL of 10% dextrose will reduce the osmolarity to a level (724 mOsmol/L) which is more favorable to the maintenance of the integrity of the walls of the veins. Intravenous fat emulsion can be infused separately or simultaneously; if infused simultaneously the fat emulsion will provide a dilution effect upon the osmolarity while increasing the energy supply.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
To reduce the risk of bacterial contamination, all intravenous administration sets should be replaced at least every 24 hours. Usage of admixtures must be initiated within 24 hours after mixing. If storage is necessary during this 24 hour period, admixtures must be refrigerated and completely used within 24 hours of beginning administration.
Login To Your Free Account